Even though none of these drugs were found to inhibit tumor development, the ability of EpCAM-AF680 NIRF imaging to capture therapeutic response in vivo shows promise for use in future treatment studies in endometrial carcinoma PDX models. This evidence concerns the gene EPCAM and endometrial carcinoma.